This page presents Genelux Corporation (NASDAQ: GNLX) SEC filings, offering insight into how the late clinical-stage biopharmaceutical company reports its activities as it develops oncolytic immunotherapies. Genelux focuses on next-generation oncolytic vaccinia virus immunotherapeutic product candidates, led by Olvi-Vec (olvimulogene nanivacirepvec), and its regulatory disclosures help investors follow governance, financing, and development-related matters.
Key filing types for GNLX include annual and quarterly reports, which discuss research and development efforts, clinical trial status for programs such as the OnPrime/GOG-3076 Phase 3 ovarian cancer trial, the VIRO-25 Phase 2 NSCLC trial, and the Olvi-Vec-SCLC-202 Phase 1b/2 SCLC trial, as well as risk factors and other business information. Definitive proxy statements (DEF 14A) provide details on board structure, director elections, equity incentive plans, and corporate governance practices, including matters submitted to stockholders at annual meetings.
Current reports on Form 8-K can describe material events such as changes to equity compensation terms, option repricing decisions under the company’s equity plans, or other board-approved actions. Registration statements and prospectus supplements associated with underwritten public offerings of common stock outline how Genelux raises capital to fund research and development, clinical trial expenses, and general corporate purposes.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as clinical program disclosures, equity plan changes, and stockholder voting outcomes. Real-time updates from EDGAR, along with access to ownership and compensation information contained in proxy materials and other filings, allow investors to monitor GNLX’s regulatory reporting as it advances its immuno-oncology pipeline.
Genelux Corporation (GNLX) Form 4 filing: Director John Thomas reported a Rule 10b5-1(c) compliant gift of 25,000 common shares on 06/06/2025, recorded under transaction code G at a price of $0. Following the transaction, Thomas directly owns 480,501 shares of GNLX. No derivative securities were involved, and there were no additional acquisitions or dispositions disclosed.
The filing indicates routine insider share reallocation rather than an open-market sale or purchase, suggesting limited immediate impact on the company’s share float or insider ownership structure.